WallStreetZenWallStreetZen

NASDAQ: DVAX
Dynavax Technologies Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DVAX

Based on 1 analyst offering 12 month price targets for Dynavax Technologies Corp

Min Forecast
$32.00+191.97%
Avg Forecast
$32.00+191.97%
Max Forecast
$32.00+191.97%

Should I buy or sell DVAX stock?

Based on 1 analyst offering ratings for Dynavax Technologies Corp.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their DVAX stock forecasts and price targets.

DVAX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-22

1 of 1

Forecast return on equity

Is DVAX forecast to generate an efficient return?

Company
N/A
Industry
286.15%
Market
228.88%

Forecast return on assets

Is DVAX forecast to generate an efficient return on assets?

Company
N/A
Industry
157.64%

DVAX earnings per share forecast

What is DVAX's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.39
Avg 2 year Forecast
$0.54
Avg 3 year Forecast
$0.78

DVAX revenue forecast

What is DVAX's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$345.5M+4.54%
Avg 2 year Forecast
$400.3M+21.11%
Avg 3 year Forecast
$460.4M+39.29%
DVAX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DVAX revenue growth forecast

How is DVAX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
11.6%
Industry
132.79%
Market
25.69%
DVAX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DVAX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DVAX vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
DVAX$10.96$32.00+191.97%Buy
AMPH$27.15$30.33+11.72%Hold
EVO$3.23N/AN/A
COLL$47.43$46.67-1.61%Strong Buy
PCRX$23.98$33.00+37.61%Strong Buy
View Top Pharmaceutical Stocks

Dynavax Technologies Stock Forecast FAQ

Is Dynavax Technologies Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: DVAX) stock is to Buy DVAX stock.

Out of 1 analyst, 0 (0%) are recommending DVAX as a Strong Buy, 1 (100%) are recommending DVAX as a Buy, 0 (0%) are recommending DVAX as a Hold, 0 (0%) are recommending DVAX as a Sell, and 0 (0%) are recommending DVAX as a Strong Sell.

If you're new to stock investing, here's how to buy Dynavax Technologies stock.

What is DVAX's earnings growth forecast for 2025-2027?

(NASDAQ: DVAX) Dynavax Technologies's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 365.63%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.81%.

Dynavax Technologies's earnings in 2025 is -$43,401,000.On average, 6 Wall Street analysts forecast DVAX's earnings for 2025 to be -$46,112,785, with the lowest DVAX earnings forecast at -$54,085,940, and the highest DVAX earnings forecast at -$36,988,865. On average, 6 Wall Street analysts forecast DVAX's earnings for 2026 to be $63,115,920, with the lowest DVAX earnings forecast at $37,975,235, and the highest DVAX earnings forecast at $80,271,708.

In 2027, DVAX is forecast to generate $91,744,127 in earnings, with the lowest earnings forecast at $50,633,646 and the highest earnings forecast at $118,364,368.

What is DVAX's revenue growth forecast for 2025-2027?

(NASDAQ: DVAX) Dynavax Technologies's forecast annual revenue growth rate of 11.6% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.69%.

Dynavax Technologies's revenue in 2025 is $330,514,000.On average, 6 Wall Street analysts forecast DVAX's revenue for 2025 to be $40,572,674,943, with the lowest DVAX revenue forecast at $38,663,344,964, and the highest DVAX revenue forecast at $41,992,342,806. On average, 6 Wall Street analysts forecast DVAX's revenue for 2026 to be $47,001,691,941, with the lowest DVAX revenue forecast at $41,443,968,206, and the highest DVAX revenue forecast at $51,429,787,485.

In 2027, DVAX is forecast to generate $54,058,932,518 in revenue, with the lowest revenue forecast at $46,182,065,665 and the highest revenue forecast at $60,750,981,444.

What is DVAX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: DVAX) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 157.64%.

What is DVAX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year DVAX price target, the average DVAX price target is $32.00, with the highest DVAX stock price forecast at $32.00 and the lowest DVAX stock price forecast at $32.00.

The Wall Street analyst predicted that Dynavax Technologies's share price could reach $32.00 by Aug 22, 2026. The average Dynavax Technologies stock price prediction forecasts a potential upside of 191.97% from the current DVAX share price of $10.96.

What is DVAX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: DVAX) Dynavax Technologies's current Earnings Per Share (EPS) is -$0.32. On average, analysts forecast that DVAX's EPS will be -$0.39 for 2025, with the lowest EPS forecast at -$0.46, and the highest EPS forecast at -$0.32. On average, analysts forecast that DVAX's EPS will be $0.54 for 2026, with the lowest EPS forecast at $0.32, and the highest EPS forecast at $0.68. In 2027, DVAX's EPS is forecast to hit $0.78 (min: $0.43, max: $1.01).

What is DVAX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: DVAX) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.